Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jerome Zeldis"'
Autor:
Rui Wang, Adam Parks, Mathias Oelke, Shweta Jain, Ruipeng Wang, Sojung Kim, Jack Ragheb, Charles Reed, Brian Alvarez, Jerome Zeldis, Daniel Bednarik
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ff3b989524db42ddac49ccdbdaf2aeaa
Autor:
Natalie Hawryluk, Li Zhiru, Clotilde Carlow, Suzanne Gokool, Simon Townson, Tamara Kreiss, Agnieszka Chojnowski, Monika Prorok, John Siekierka, Alexandra Ehrens, Marianne Koschel, Nathaly Lhermitte-Vallarino, Coralie Martin, Achim Hoerauf, Geraldine Hernandez, Stacie Canan, Vikram Khetani, Jerome Zeldis, Sabine Specht, Marc P. Hübner, Ivan Scandale
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 19, Iss , Pp 89-97 (2022)
Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastating of all tropical diseases, affecting over 86 million people worldwide. To control and more rapidly eliminate onchocerciasis requires treatm
Externí odkaz:
https://doaj.org/article/68b02e6e71f1432399da4c59040a7b3a
Autor:
David Langan, Ruipeng Wang, Keshanti Tidwell, Selome Mitiku, Alison Farrell, Catrina Johnson, Adam Parks, Lauren Suarez, Shweta Jain, Sojung Kim, Kristi Jones, Mathias Oelke, Jerome Zeldis
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
In addition to complications of acute diseases, chronic viral infections are linked to both malignancies and autoimmune disorders. Lack of adequate treatment options for Epstein-Barr virus (EBV), Human T-lymphotropic virus type 1 (HTLV-1), and human
Externí odkaz:
https://doaj.org/article/bab7d5dbad5b4c3d88ccad35b0e870dd
Autor:
Mital Gandhi, Mathias Oelke, Sojung Kim, Ruipeng Wang, Keshanti Tidwell, Elena Cassella, Shaina Anuncio, Mark Batistick, Manpreet Bariana, Jack A Ragheb, Jerome Zeldis, Johannes Zakrzewski
Publikováno v:
Transplantation and Cellular Therapy. 29:S393
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::488fc727ad6123cb222ee9feba6d26c0
https://doi.org/10.1016/s2666-6367(23)00593-6
https://doi.org/10.1016/s2666-6367(23)00593-6
Autor:
Birger, Sørensen, Maja A, Sommerfelt, Grete, Stjernholm, Peter Lawrence, Smith, Mats, Ökvist, Arnt-Ove, Hovden, Gunnar, Hoddevik, Robert, Redfield, Valentina, Ustina, Øyvind, Jelmert, Jerome, Zeldis, Angus, Dalgleish
Publikováno v:
AIDS research and human retroviruses. 33(6)
Antibodies to the carboxy-terminal constant (C5) region 5 of the HIV-1 envelope glycoprotein gp120 have previously been associated with slow disease progression. This is one of the regions on gp120 that interact with the transmembrane glycoprotein, g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3da674c7db9afd5ac83d77e5095b6253
https://pubmed.ncbi.nlm.nih.gov/28051320
https://pubmed.ncbi.nlm.nih.gov/28051320
Autor:
John C Hardaway, Louis F. Chai, Mikayla Lopes, Benjamin Rabinowitz, Prajna Guha, David Jaroch, Bryan Cox, Robert Knight, Jerome Zeldis, N. Joseph Espat, Steven C Katz
Publikováno v:
The Journal of Immunology. 202:130.1-130.1
Introduction We have demonstrated safety and clinical activity with anti-CEA CAR-T (Sorrento/TNK Therapeutics, Inc.) regional infusions for treatment of liver metastases (LM) using a pressure-enabled drug delivery device (PEDD™, TriSalus™ Life Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fda8d91f06ecd4f866b19560752788b9
https://doi.org/10.4049/jimmunol.202.supp.130.1
https://doi.org/10.4049/jimmunol.202.supp.130.1
Autor:
Guillermo Garcia-Manero, R N Sherry Pierce, Jorge E. Cortes, Srdan Verstovsek, Susan O'Brien, Jerome Zeldis, Francis J. Giles, Maher Albitar, Michael J. Keating, Hagop Kantarjian, Deborah A. Thomas, Stefan Faderl
Publikováno v:
Cancer. 106(9)
BACKGROUND Thalidomide is a putative antiangiogenesis agent with activity in several hematologic malignancies. METHODS Forty-four patients who had myelofibrosis with myeloid metaplasia received treatment with thalidomide in a Phase II clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc09ba6771683f6b22905913464950e
https://pubmed.ncbi.nlm.nih.gov/16583431
https://pubmed.ncbi.nlm.nih.gov/16583431
Autor:
Maria Teresa Petrucci, Mario Boccadoro, Robert Knight, Jerome Zeldis, Sara Bringhen, Maria Teresa Ambrosini, Ilaria Avonto, Francesca Gay, Paola Omedè, Antonietta Falcone, Annalisa Luraschi, Fortunato Morabito, Nicola Giuliani, Giuseppe Rossi, Francesco Di Raimondo, Paolo Corradini, Pellegrino Musto, Patrizia Falco, Antonio Palumbo
Introduction. Lenalidomide (RevlimidR) is a novel, orally active immunomodulatory drug effective for the treatment of refractory myeloma. In this multicenter trial, we evaluate the potential additive and synergistic effect of the combination Revlimid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97296c36953c836fe119aea48f251843
http://hdl.handle.net/2318/121844
http://hdl.handle.net/2318/121844
Autor:
Azra Raza, Diya Dutt, Peter M. Meyer, Cathryn Goldberg, Saleem Dar, Parameswaran Venugopal, Francesca Zorat, Sefer Gezer, Jerome Zeldis, Fabiana Nascimben, Laurie Lisak, Jerome Loew, Morne du Randt, Christopher Kaspar
Publikováno v:
Blood. 98(4)
Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped therapy before 12 weeks (minimum period for response evaluation), an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6e2d142b6a071da7b3d48be580190bd
https://pubmed.ncbi.nlm.nih.gov/11493439
https://pubmed.ncbi.nlm.nih.gov/11493439
Autor:
Deborah A. Thomas, Francis J. Giles, Maher Albitar, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Susan M. O'Brien, Guillermo Garcia‐Manero, Michael J. Keating, Sherry Pierce, Jerome Zeldis, Hagop M. Kantarjian
Publikováno v:
Cancer (0008543X); Apr2006, Vol. 106 Issue 9, p1974-1984, 11p